NCT01499199View on ClinicalTrials.gov

A Study of the Pharmacokinetics and Antiviral Activity of Dolutegravir in the Central Nervous System in HIV-1 Infected ART-naive Subjects

PHASE3CompletedINTERVENTIONAL
Enrollment

13

Participants

Timeline

Start Date

January 31, 2012

Primary Completion Date

October 31, 2012

Study Completion Date

May 31, 2014

Conditions
Infection, Human Immunodeficiency Virus
Interventions
DRUG

Dolutegravir

50mg Once Daily

Trial Locations (3)

90069

GSK Investigational Site, Los Angeles

92103

GSK Investigational Site, San Diego

02906

GSK Investigational Site, Providence

Sponsors

Lead Sponsor

ViiV Healthcare

Collaborators (2)

Shionogi
GlaxoSmithKline
All Listed Sponsors
collaborator

Shionogi

INDUSTRY

collaborator

GlaxoSmithKline

INDUSTRY

lead

ViiV Healthcare

INDUSTRY